Clinical trials: Sporadic Inclusion Body Myositis
Inclusion Body Myositis
Cell Therapy for IBM by Muscle Injection of ADSVF
Inclusion Body Myositis is a slowly but disabling myopathy, the most frequent in patients over 50 years old. No treatments (in particular immunosuppressive) are known to be efficient.
- Trial name
- ADSVF-in-IBM (NCT05032131)
- Testing
- ADSVF
- Where
- France
- Volunteers
- 32 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Polymyositis, Dermatomyositis
Anakinra in Myositis
To investigate the effect of the interleukin-1 (IL-1) blocking agent, anakinra, in patients with treatment-resistant inflammatory myopathies.
- Conditions
- Polymyositis, Dermatomyositis, Inclusion Body Myositis
- Trial name
- NCT01165008
- Testing
- Anakinra
- Where
- Sweden
- Sponsor
- Karolinska Institutet
Inclusion Body Myositis (IBM)
Natalizumab in Inclusion Body Myositis (IBM)
Muscle biopsies of patients with Inclusion Body Myositis (IBM) have demonstrated a T-cell predominant inflammatory infiltrate, therefore, new agents targeting T -cell mediated cell death may be a novel treatment for IBM.
- Trial name
- IBM-NAT (NCT02483845)
- Testing
- Natalizumab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Phoenix Neurological Associates, LTD
Inclusion Body Myositis (IBM)
Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis
Sporadic Inclusion Body Myositis (IBM) is the most frequent inflammatory myopathy in patients over 50. It is a slowly progressive, but today untreatable (notably by classical immunosuppressants) disease.
- Trial name
- RAPAMI (NCT02481453)
- Testing
- Rapamycin
- Where
- France
- Volunteers
- 44 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Sporadic Inclusion Body Myositis
Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients
This study evaluated the efficacy, safety and tolerability of multiple doses of bimagrumab/BYM338 vs placebo, when administered intravenously (i.v.), on physical function, muscle strength, and mobility in patients with sporadic…
- Trial name
- RESILIENT (NCT01925209)
- Testing
- BYM338/bimagrumab
- Where
- 38 sites in United States, Australia and 8 more
- Volunteers
- 251 people
- Sponsor
- Novartis Pharmaceuticals
Pompe Disease (Late-onset), Inclusion Body Myositis
Pompe & Pain - Study to Assess Nociceptive Pain in Adult Patients With Pompe Disease
The primary aim of this nationwide, explorative, cross-sectional study in Germany is to characterize the prevalence, severity and quality of musculoskeletal pain in adult patients with late-onset Pompe disease (LOPD).
- Conditions
- Pompe Disease (Late-onset), Inclusion Body Myositis, Spinal Muscular Atrophy Type 3, FSHD
- Trial name
- NCT05272969
- Testing
- Beck depression inventory fast screen (Questionnaire), Brief Pain Inventory (BPI) (Questionnaire), German Pain Inventory (Questionnaire)
- Where
- Germany
- Volunteers
- 95 people
- Sponsor
- LMU Klinikum
Becker Muscular Dystrophy, Sporadic Inclusion Body Myositis
Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis
The investigators are performing a gene therapy clinical trial in Becker muscular dystrophy (BMD) and sporadic inclusion body myositis (sIBM) patients.
- Trial name
- NCT01519349
- Testing
- rAAV1.CMV.huFollistatin344
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Nationwide Children's Hospital
Inclusion Body Myositis, Sporadic, Inclusion Body Myopathy, Autosomal-recessive
Natural History in CCFDN and IBM Syndromes
So far, only limited data is available regarding the natural course in Congenital Cataract Facial Dysmorphism Neuropathy Syndrome (CCFDN) and sporadic and hereditary inclusion body myopathies (IBM).
- Conditions
- Inclusion Body Myositis, Sporadic, Inclusion Body Myopathy, Autosomal-recessive, Inclusion Body Myopathy, Autosomal-dominant, Congenital Cataracts, Facial Dysmorphism, And Neuropathy
- Trial name
- NCT01902940
- Testing
- Natural History
- Where
- Germany
- Volunteers
- 350 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Inclusion Body Myositis
A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients With (IBM)
An open-label, ascending dose study for adult patients with Inclusion Body Myositis (IBM).
- Trial name
- NCT04659031
- Testing
- ABC008
- Where
- 4 sites in Australia
- Volunteers
- 19 people
- Sponsor
- Abcuro, Inc.
Inclusion Body Myositis
Monitoring Biomarker for Detecting Change in Physical Activity and Limb Function in Inclusion Body Myositis Over Time
Inclusion-Body Myositis (IBM) results in weakness and the deterioration of distal arm muscles, the symptoms of which are currently assessed through expert examination at clinical visits.
- Trial name
- NCT06153108
- Testing
- PAMSys pendant PAMSys wrist sensors
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Kansas Medical Center
Inclusion Body Myositis, Myotonic Dystrophy 1
The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Training Period.
The planned project is an intervention study to assess the risk of falling after adaptation of an assistive gait devices in patients with the following neuromuscular diseases: Inclusion body myositis, myotonic dystrophy, limb…
- Conditions
- Inclusion Body Myositis, Myotonic Dystrophy 1, Myotonic Dystrophy 2, Facio-Scapulo-Humeral Dystrophy
- Trial name
- Risk of fall (NCT07072676)
- Testing
- Assistive gait devices combined with physiotherapy
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- LMU Klinikum
Sporadic Inclusion Body Myositis
An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203
This extension study will provide data to further evaluate the efficacy, safety, and tolerability of three doses of BYM338 and to assess the long-term effects of BYM338 in patients with sporadic inclusion body myositis.
- Trial name
- NCT02573467
- Testing
- Bimagrumab
- Where
- 38 sites in United States, Australia and 8 more
- Volunteers
- 211 people
- Sponsor
- Novartis Pharmaceuticals
Inclusion Body Myositis (IBM), Feasibility Study
Exercise as Treatment for Patients With Inclusion Body Myositis
There is little knowledge about exercise for patients with inclusion body myositis (IBM). Patients with IBM have limited access to rehabilitation and physiotherapy resources, despite a significant need for these services due to…
- Trial name
- NCT06644482
- Testing
- Exercise group in a hospital setting
- Where
- Norway
- Volunteers
- 15 people
- Sponsor
- Oslo University Hospital
Inclusion Body Myositis
IBM Dietary Surveillance Study
The goal of this observational study is to understand how diet may influence the disease characteristics of inclusion body myositis (IBM).
- Trial name
- NCT07535996
- Testing
- Whole-Body Dual-Energy X-ray Absorptiometry, Anthropometry, Capillary Blood Sampling
- Where
- United Kingdom
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Manchester Metropolitan University
Sporadic, Inclusion Body
Immune Abnormalities in Sporadic Inclusion Body Myositis
This study will examine the abnormal immune response in patients with sporadic inclusion body myositis (s-IBM)-the most common inflammatory muscle disease in people over the age of 50.
- Conditions
- Sporadic, Inclusion Body, Myositis
- Trial name
- NCT00030212
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Inclusion Body Myositis, Sporadic Inclusion Body Myositis
Safety and Tolerability of Phenylbutyrate in Inclusion Body Myositis
This is a pilot study (phase 1 clinical trial) to evaluate the safety and tolerability of phenylbutyrate in IBM. In this open label study, 10 patients with sporadic inclusion body myositis will be treated with phenylbutyrate (3…
- Trial name
- NCT04421677
- Testing
- Phenylbutyrate Oral Tablet
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Kansas Medical Center
Neuromuscular Diseases (NMD), Amyotrophic Lateral Sclerosis
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
This single-arm pilot study evaluates the effects of whole-body electrical muscle stimulation (WB-EMS) exercise on neuromuscular and physical function in adults with neuromuscular disease (NMD).
- Conditions
- Neuromuscular Diseases (NMD), Amyotrophic Lateral Sclerosis, Myasthenia Gravis, Lambert-eaton Myasthenic Syndrome
- Trial name
- NCT07478172
- Testing
- Whole-body Electrical Muscle Stimulation Exercise
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Missouri-Columbia
Sporadic Inclusion Body Myositis
Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis
The primary objective of the study is to evaluate the efficacy of REGN2477+REGN1033 in combination on total lean mass, as measured by Dual-energy X-ray absorptiometry (DXA) in patients with sporadic inclusion body myositis…
- Trial name
- NCT03710941
- Testing
- REGN2477+REGN1033
- Sponsor
- Regeneron Pharmaceuticals
Dermatomyositis, Inclusion Body Myositis
Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies
Inflammatory myopathies are a group of muscle diseases characterized by muscle weakness, high levels of muscle enzymes in the blood, and inflammation of the tissue surrounding muscle fibers (endomysium).
- Conditions
- Dermatomyositis, Inclusion Body Myositis, Polymyositis
- Trial name
- NCT00001261
- Testing
- Gamma Globulin
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Sporadic Inclusion Body Myositis (sIBM), Idiopathic Inflammatory Myopathies
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis
To evaluate the efficacy of Pozelimab/Cemdisiran combination therapy in patients with sIBM
- Trial name
- NCT06479863
- Testing
- Pozelimab/Cemdisiran
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Austin Neuromuscular Center